Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries

Journal of Invasive Cardiology

Volumn 18, Issue 8, 2006, Pages 383-390

  Jabara, Refat ^a   Chronos, Nicolas ^a   Tondato, Fernando ^a   Conway, Damian ^b   Molema, Warner ^b   Park, Kenneth ^b   Mabin, Tom ^c   King, Spencer ^a   Robinson, Keith ^a  

^a Saint Joseph's Hospital of Atlanta   (United States)

^b DISA Vascular   (South Africa)

^c Vergelegen Medi Clinic   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

METAL; PACLITAXEL; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTERY MUSCLE; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; ELUTION; HISTOPATHOLOGY; IN VITRO STUDY; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MATERIAL COATING; MEASUREMENT; MORPHOMETRICS; MUSCLE NECROSIS; NONHUMAN; STATISTICAL ANALYSIS; SWINE;

ABSORBABLE IMPLANTS; ANIMALS; CORONARY STENOSIS; CORONARY VESSELS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; MUSCLE, SMOOTH, VASCULAR; NECROSIS; PACLITAXEL; POLYMERS; STENTS; SWINE; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33746783755     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Virmani R, Kolodgie FD, Farb A. Drug-eluting stents: Are they really safe? Am Heart Hosp J 2004;2:85-88.
2. Schwartz RS, Chronos N, Virmani R. Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol 2004;44:1373-1385.
3. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-2332.
4. Hong MK, Kornowski R, Bramwell O, et al. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 2001;12:513-515.
5. Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 2003;107:777-784.
6. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-2295.
7. Rogers CD. Drug-eluting stents: Clinical perspectives on drug and design differences. Rev Cardiovasc Med 2005;6(Suppl 1):S3-S12.
8. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
9. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-705.
10. Vermani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: Caution and concerns for long term outcome. Coron Artery Dis 2004;15:313-318.
11. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.
12. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: Recommended evaluation from a consensus group. Circulation 2002;106:1867-1873.
13. Baek N, Lee J, Park K. Aqueous N, N-diethylnicotinamide solution as a medium for accelerated release study of paclitaxel. J Biomater Sci Polymer Edn 2004;15:527-542.
14. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-230.
15. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992;19:267-274.
16. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
17. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
18. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
19. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-230.
20. Moses JW, Mehran R, Nikolsky E, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: Analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1165-1171.
21. Stone GW, Ellis SG, Cox DA, et al. TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004;109:1942.
22. Robinson K, Chronos N, Royal J, et al. Actinomycin-D drug-eluting stents preserve lumen size and inhibit fibrocellular neointima in pig coronary arteries. Circulation 2001;104:2396 II-506.
23. Robinson KA, Serruys P, Stack RS, Virmani R. Results and lessons learned form unsuccessful drug-eluting stent programs: Failure of the actinomycin D coating to inhibit in-stent restenosis despite potent biologic effects in pig coronary arteries. In: Stone GW, Serruys PW, Baim DS, et al (eds.) Textbook of Coronary Stenting (1st Editon) (in press).
24. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004;63:617-624.
25. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
26. Hwang CW, David AB, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001;104:600-605.
27. Rogers CD. Optimal stent design for drug delivery. Rev Cardiovasc Med 2004;(5 Suppl )2:S9-S15.
28. Hwang CW, Wu D, Edelman ER. Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Interv 2003;5:7-12.
29. Virmani R, Kolodgie FD, Farb A, Lafant A. Drug eluting stents: Are human and animal studies comparable? Heart 2003;89:133-138.